Chen, Zhangwei – Trademark Portfolio

Entity Type: 01

Chen, Zhangwei holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 14 (Jewelry) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include HAOSHUFU, PRINCESSGIFT, and ENCHANTED GIFT. The owner is based in Leiyang City, Hunan.

No. 80, Liyuan New Village

Room 402, Unit 1, Building 1

Leiyang City, Hunan 421800 , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Chen, Zhangwei's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

14
Jewelry (3 filings)

Precious metals and their alloys; jewellery, precious stones; horological instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Chen, Zhangwei have?

Chen, Zhangwei has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending.

What trademark classes does Chen, Zhangwei file in?

Chen, Zhangwei files trademarks across 2 Nice Classification classes. The most active classes are Class 14 (Jewelry), Class 5 (Pharmaceuticals). Class 14 covers precious metals and their alloys; jewellery, precious stones; horological instruments.

What are Chen, Zhangwei's most well-known trademarks?

Chen, Zhangwei's registered trademark portfolio includes well-known marks such as HAOSHUFU, PRINCESSGIFT, and ENCHANTED GIFT. These are among 3 currently registered trademarks in the portfolio.

What is Chen, Zhangwei's trademark registration success rate?

Chen, Zhangwei has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 1 application is pending review.